Search research articles
Contact Us
Filters
Showing results (31-40 of 66) with videos related to
Page
of 7
Sort By:
CPT: Pharmacometrics & Systems Pharmacology
|
October 8, 2020
Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A
Yukio Otsuka, Mary P Choules, Peter L Bonate, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2025
Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Akihiro Yamada, Jianning Yang, Peter L Bonate, et al.
Antimicrobial Agents and Chemotherapy
|
June 20, 2018
Pharmacokinetics of a Pediatric Tribendimidine Dose-Finding Study To Treat Hookworm Infection in African Children
Noemi Hiroshige, Jean Coulibaly, Jörg Huwyler, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 19, 2024
Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine
André Dallmann, Peter L Bonate, Janelle Burnham, et al.
Journal of Clinical Pharmacology
|
April 8, 2025
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug-Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
Mary P Choules, Yukio Otsuka, Jace C Nielsen, et al.
Clinical and Translational Science
|
July 3, 2025
Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
Akihiro Yamada, Masato Takeuchi, Kanji Komatsu, et al.
The AAPS Journal
|
January 4, 2008
Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite
Peter L Bonate, David Beyerlein, Jennifer Crawford, et al.
Antimicrobial Agents and Chemotherapy
|
July 7, 2016
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
Amit Desai, Laura Kovanda, Donna Kowalski, et al.
Journal of Clinical Pharmacology
|
November 25, 2024
Sentinel Dosing-Time for a Risk-Based Approach?
Peter L Bonate, Mark Rogge, Jean-Michel Gries, et al.
Nature Reviews. Drug Discovery
|
October 4, 2006
Discovery and development of clofarabine: a nucleoside analogue for treating cancer
Peter L Bonate, Larry Arthaud, William R Cantrell, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 66) with videos related to
Sort By:
Page
of 7
CPT: Pharmacometrics & Systems Pharmacology
|
October 8, 2020
Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A
Yukio Otsuka, Mary P Choules, Peter L Bonate, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2025
Population pharmacokinetic analysis of fluorouracil and oxaliplatin in the absence or presence of zolbetuximab in locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Akihiro Yamada, Jianning Yang, Peter L Bonate, et al.
Antimicrobial Agents and Chemotherapy
|
June 20, 2018
Pharmacokinetics of a Pediatric Tribendimidine Dose-Finding Study To Treat Hookworm Infection in African Children
Noemi Hiroshige, Jean Coulibaly, Jörg Huwyler, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 19, 2024
Enhancing inclusivity in clinical trials: Model-informed drug development for pregnant individuals in the era of personalized medicine
André Dallmann, Peter L Bonate, Janelle Burnham, et al.
Journal of Clinical Pharmacology
|
April 8, 2025
Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug-Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
Mary P Choules, Yukio Otsuka, Jace C Nielsen, et al.
Clinical and Translational Science
|
July 3, 2025
Population PK and Exposure-Response Analyses of Zolbetuximab in Patients With Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
Akihiro Yamada, Masato Takeuchi, Kanji Komatsu, et al.
The AAPS Journal
|
January 4, 2008
Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite
Peter L Bonate, David Beyerlein, Jennifer Crawford, et al.
Antimicrobial Agents and Chemotherapy
|
July 7, 2016
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
Amit Desai, Laura Kovanda, Donna Kowalski, et al.
Journal of Clinical Pharmacology
|
November 25, 2024
Sentinel Dosing-Time for a Risk-Based Approach?
Peter L Bonate, Mark Rogge, Jean-Michel Gries, et al.
Nature Reviews. Drug Discovery
|
October 4, 2006
Discovery and development of clofarabine: a nucleoside analogue for treating cancer
Peter L Bonate, Larry Arthaud, William R Cantrell, et al.
Page
of 7